As the rise of diabetes is undeniably ongoing, more studies are primed into understanding potential complications and risks that can arise from the regular introduction and intervention of diabetes drugs.
One such drug, pioglitazone, is suggested to have increased risks in the development of bladder cancer, as recent studies indicate.
The study, conducted by Canada-based researchers, reveal that the regular treatment dosage of the drug increases the risk of bladder cancer by twice its standard normal risk factors.
Analyzing the records of over 115,000 patients taking the drug, researchers found out that there has been a lead up of 137 extra bladder cancer patients per 100,000 persons in an 11 year timeframe. The records were taken from different persons based in the United Kingdom.
Posting and writing their study’s results on the online British Medical Journal, members of the research team suggest that their study, and the results, “provide proof that pioglitazone is associated with an increased risk of bladder cancer.”
Note that the study tells that the drug poses to be an increased risk for bladder cancer and not a likely cause.
A number of researchers have also countered the study’s claims, pointing out that other considerations that could have most likely caused the increased risk of bladder cancer state.
Bottom line, it is advisable for diabetics to have regular checkups, not necessarily in relation to the study’s recent discoveries, but in an effort to ensure that constitutions are well maintained and healthy.
Healthcare professionals should also be keen on noting updates, pertaining to the drug and its possible effect in the onset of bladder cancer.
